Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intramuscular,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | India | Malaysia | Philippines | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Monash University Malaysia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Skin Cancer|Tuberculosis, Cutaneous|Lung Diseases, Fungal|Malaria|Diphtheria|Tuberculosis, Oral|Immune Complex Diseases|Skin Diseases, Bacterial|HIV Infections|Salmonella Infections, Animal|Skin Diseases, Genetic|Influenza, Human|Lung Cancer|Inflammation|Skin Diseases, Infectious|Gram-Negative Bacterial Infections|Measles
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12624001057572 | N/A |
Not yet recruiting |
Unknown |
2025-06-30 |
|
21HH6540 | N/A |
Completed |
Healthy Volunteers |
2022-07-20 |
|
BYI-0736 | P1 |
Completed |
Salmonella Infections, Animal|Skin Diseases, Bacterial|Influenza, Human|HIV Infections|Skin Cancer|Inflammation|Tuberculosis, Cutaneous|Gram-Negative Bacterial Infections|Measles|Lung Cancer|Lung Diseases, Fungal|Diphtheria|Malaria|Skin Diseases, Infectious|Skin Diseases, Genetic|Immune Complex Diseases|Tuberculosis, Oral |
2013-03-01 |